Livagen
Hepatic / DetoxificationAlso known as: Lys-Glu-Asp-Ala, KEDA
Mechanism
A tetrapeptide bioregulator that targets liver tissue. It modulates liver cell gene expression and promotes hepatocyte regeneration. Khavinson's research demonstrated that Livagen causes structural changes in liver cell chromosomes (decondensation of heterochromatin), essentially "unlocking" silenced genes needed for liver cell renewal.
Technical detail
Synthetic tetrapeptide (Lys-Glu-Asp-Ala) targeting hepatic tissue. Key finding: induces decondensation of pericentromeric heterochromatin in hepatocyte nuclei, specifically in chromosomal regions 1q12 and 16q11 (Khavinson & Lezhava, 2003). This chromatin remodeling reactivates gene expression silenced during aging. In vitro studies show Livagen-treated hepatocytes exhibit increased ribosomal gene transcription and protein synthesis. Proposed mechanism: direct peptide-DNA interaction at AT-rich heterochromatic regions, displacing HP1 protein and enabling transcriptional access. Published in Bulletin of Experimental Biology and Medicine.
Effects
**Hepatic System (Tier 2 — Animal + In Vitro):** Livagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Ala) from the Khavinson peptide bioregulator family, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It selectively modulates gene expression in hepatocytes, promoting liver tissue repair and normalization of protein synthesis. Animal studies show restoration of liver function markers (ALT, AST, albumin synthesis) in toxic liver damage models. **Chromatin & Gene Expression (Tier 2 — In Vitro):** Livagen has been shown to decondense heterochromatin in hepatocyte nuclei, increasing transcriptional accessibility of genes involved in liver regeneration and detoxification. This epigenetic mechanism is characteristic of the Khavinson bioregulator peptides — small peptides that interact directly with DNA to modulate gene expression in a tissue-specific manner. **Immune Modulation (Tier 3 — Preclinical):** Some evidence of hepatic immune modulation — promotes Kupffer cell normalization and reduces inflammatory cytokine production in liver tissue. May support immune surveillance in the hepatic microenvironment. **Aging & Hepatic Senescence (Tier 2 — Animal):** In aged animal models, Livagen treatment partially restored youthful gene expression patterns in liver tissue, including upregulation of detoxification enzymes (cytochrome P450 family) and albumin synthesis genes that decline with age.
Practitioner Guide
**CONTEXT:** • Livagen is part of the Khavinson bioregulator peptide system developed in Russia. These are short peptides (2–4 amino acids) designed to target specific organs by interacting with tissue-specific DNA sequences. • Available primarily through European and Russian suppliers. Not widely used in North American peptide therapy practices. • Limited Western clinical data — most evidence is from Russian-language publications and the Khavinson research group. **DOSING (Based on Khavinson Protocols):** • Oral capsule: 10 mg daily for 10–30 days. The bioregulator peptides are designed for oral administration — their small size allows GI absorption. • Cycles: 10-day course, repeated every 3–6 months. Some protocols use 30-day courses for more significant liver pathology. • Can be combined with other Khavinson bioregulators (e.g., Ovagen for GI, Visoluten for eyes, etc.) in a multi-organ "bioregulation" protocol. **CLINICAL PEARLS:** • Livagen is positioned as a hepatoprotective supplement, not a treatment for acute liver disease. • Best suited for: age-related liver function decline, post-hepatotoxic exposure support, and general liver health optimization in the bioregulator framework. • Minimal side effect profile reported. No known drug interactions documented, though data is limited. • Western practitioners who use Livagen typically incorporate it within a broader Khavinson bioregulator program alongside lifestyle liver support (NAC, milk thistle, etc.).
Research Summary
**Tier 1 (Human Clinical Evidence):** • Limited. Small Russian clinical studies report improvement in liver function tests and subjective well-being in patients with chronic hepatitis and toxic liver damage. Studies are not to Western RCT standards — small sample sizes, limited blinding, and published primarily in Russian journals. **Tier 2 (Strong Preclinical + Mechanistic):** • Khavinson group publications demonstrate heterochromatin decondensation in hepatocyte nuclei with Livagen exposure. Mechanism is consistent across multiple in vitro studies — short peptides interacting with histone proteins and DNA to modulate transcription. • Animal toxicity models: Livagen accelerated recovery from CCl4-induced liver damage in rats, normalizing ALT/AST and restoring liver histology faster than controls. • The broader Khavinson bioregulator research program has published hundreds of papers, though most are in Russian-language journals with limited Western peer review. **Tier 3 (Emerging / Theoretical):** • The concept of tissue-specific peptide bioregulators interacting with DNA is scientifically intriguing but not widely accepted in Western medicine. The mechanism of how a 4-amino-acid peptide achieves tissue specificity is not fully elucidated. • Anti-aging claims (restoring youthful gene expression) are based on animal chromatin studies and require human validation.